Anavex Life Sciences Corp (AVXL)

[Joseph_K]

Regarding P3 versus P4: We're about two inches away from what might be called "a purely semantic disagreement." We can go on showing (or not showing) what clever interpreters of FDA bureaucracy and lingo we are, but I see no difference between our opinions that matters. Blarcamesine will almost certainly go through an additional clinical trial for Alzheimer's, and the FDA, if it is sufficiently pleased with the results of the P2b/3 (including the surrogate biomarkers), will permit Anavex to market blarcamesine for Alzheimer's while the new trial -- whatever the FDA or Anavex or any of us calls it -- is underway. It's all good.